Read/Write Labs rebrands Dandelion to build an AI platform for brain therapies
Read/Write Labs, based in Boston and Geneva, says it is developing software to turn brain models into therapies. Its public materials describe the goal and an earlier Wyss Center partnership, but show no product demo, customer list or clinical validation of the current platform.
By Ryan Merket · Published
Primary source: PR Newswire Business Technology
Why it matters
Read/Write Labs is trying to turn brain-modeling research into a therapeutic platform, with Hanina's health-tech operating experience and Schrimpf's NeuroAI work behind the effort. The company has described its ambition and earlier research partnership; its public materials do not yet show that the current platform has produced a treatment or clinical result.
Read/Write Labs, formerly Dandelion Science, has rebranded around a plan to develop AI for brain therapies under founder and CEO Adam Hanina. Read/Write Labs, based in Boston and Geneva, announced the new name and an expanded executive team and group of advisors on October 28th, 2026.…
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.